Diamyd Medical AB (OSTO:DMYD B) Interest Expense : kr-0.80 Mil (TTM As of Feb. 2025)

View and export this data going back to 2013. Start your Free Trial

What is Diamyd Medical AB Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Diamyd Medical AB's interest expense for the three months ended in Feb. 2025 was kr -0.24 Mil. Its interest expense for the trailing twelve months (TTM) ended in Feb. 2025 was kr-0.80 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Diamyd Medical AB's Operating Income for the three months ended in Feb. 2025 was kr -45.69 Mil. Diamyd Medical AB's Interest Expense for the three months ended in Feb. 2025 was kr -0.24 Mil. Diamyd Medical AB did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Diamyd Medical AB Interest Expense Historical Data

The historical data trend for Diamyd Medical AB's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB Interest Expense Chart

Diamyd Medical AB Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

Interest Expense

Get a 7-Day Free Trial

-0.53

-0.45

-0.25

-0.01

Diamyd Medical AB Quarterly Data
	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25
Interest Expense	Get a 7-Day Free Trial															-0.49	-	2.08	-2.63	-0.24

Diamyd Medical AB Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Feb. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.80 Mil.

Diamyd Medical AB (OSTO:DMYD B) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Diamyd Medical AB's Interest Expense for the three months ended in Feb. 2025 was kr-0.24 Mil. Its Operating Income for the three months ended in Feb. 2025 was kr-45.69 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Feb. 2025 was kr0.00 Mil.

Diamyd Medical AB's Interest Coverage for the quarter that ended in Feb. 2025 is calculated as

Diamyd Medical AB did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Diamyd Medical AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

DYMDF:USA DMN:Germany

Address

Kungsgatan 29, Stockholm, SWE, SE-111 56

Website

https://www.diamyd.com

Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB Headlines

No Headlines